Cancer researchers identify new function in an old acquaintance

Cells have two different programs to safeguard them from getting out of control and developing cancer. One of them is senescence (biological aging). It puts cancer cells into a permanent sleep so they no longer divide and grow in an uncontrolled way. Now the research group led by Professor Walter Birchmeier (Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch) has discovered that an enzyme known to be active in breast cancer and leukemia blocks this protection program and boosts tumor growth. They succeeded in blocking this enzyme in mice with breast cancer, thus reactivating senescence and stopping tumor growth (EMBO-Journal, DOI 10.15252/embj.201489004)*.

Inhibition of the tyrosine phosphatase Shp2 in breast cancers of PyMT mice...
Inhibition of the tyrosine phosphatase Shp2 in breast cancers of PyMT mice induces senescence. In senescence, cells become large, express the enzyme beta-Galatosidase, which creates blue color upon staining, and lead to permanent growth arrest.
Source: Graphic: Linxiang Lan/Copyright: MDC

The enzyme Shp2 belongs to a group of enzymes called tyrosine phosphatases. These enzymes are major cell growth regulators. Shp2, for example, plays an essential role in early embryogenesis and is also known to play a role in cancer. Some years ago researchers showed that Shp2 is upregulated in 70 percent of invasive breast cancers. These forms of breast cancer are particularly aggressive. Recent studies with human breast cancer cell lines have also shown that Shp2 mediates survival signals in cancer cells.

Reason enough for MDC cancer researcher Professor Birchmeier, who for years has been studying signaling in cancer, to further investigate this enzyme with his research team colleagues Dr. Linxiang Lan and Dr. Jane Holland. Also, current evidence shows that senescence may play an inhibitory role in breast cancer.

The MDC researchers therefore studied mice which carried the breast cancer gene PyMT. This oncogene rapidly initiates breast cancer, which also metastasizes. The researchers noted that the enzyme Shp2 is very active in these mice. They were able to show that Shp2 initiates a signaling cascade. Within this cascade Shp2 turns on different signaling molecules, but turns off the tumor suppressor genes p27 und p53. As a result, the senescence protection program is also shut off.

The question of interest was whether or not senescence can be turned on again. Is it possible to target Shp2 directly and shut it off? Using a small molecule, researchers of the biotech company Experimental Pharmacology and Oncology (EPO), based on the Berlin-Buch campus as is the MDC, were able to shut down the Shp2 gene in the mice with breast cancer. In this way they were able to reactivate the senescence program and stop the growth of the breast cancer cells. The small molecule was developed by the Leibniz-Institut für molekulare Pharmakologie (FMP) in Berlin-Buch. However, it is still an experimental drug and has not been licensed for use in human patients.

The next step was to find out which role Shp2 and its target genes play in human patients with breast cancer. Dr. Balázs Györffy of Semmelweiss University in Budapest, Hungary, a longtime collaborator of Professor Birchmeier, looked at the retrospective data of almost 4,000 patients. After analyzing the data, he and his collaborators in Berlin are convinced that the activity of Shp2 and its target genes can predict the outcome of breast cancer: The less active Shp2 is, the higher the chance for the affected women to stay relapse-free after having undergone a successful breast cancer therapy.

“Our data suggest that senescence induction by inhibiting Shp2 or controlling its targets may be useful in therapeutic approaches to breast cancer,” the researchers conclude. Cancer cells in the senescence mode secrete messenger molecules of the immune system (cytokines), enabling the body’s defense system to identify these sleeping cancer cells and destroy them.

*Shp2 Signaling is Essential to the Suppression of Senescence in PyMT-induced Mammary Gland Cancer in Mice
Linxiang Lan1, Jane D. Holland1, Jingjing Qi1, Stefanie Grosskopf1, Regina Vogel1, Balázs Györffy2,3, Annika Wulf-Goldenberg4, Walter Birchmeier1,*
1 Cancer Research Program, Max Delbrück Center for Molecular Medicine (MDC) Berlin, Germany
2 MTA TTK Lendület Cancer Biomarker Research Group, Budapest, Hungary
3 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary
4 Experimental Pharmacology & Oncology (EPO), Berlin, Germany

Source: Press release Max-Delbrück-Centrum für Molekulare Medizin (MDC) Berlin-Buch

17.03.2015

Read all latest stories

Related articles

Photo

Animal testing

Can mice really mirror humans when it comes to cancer?

A new Michigan State University study is helping to answer a pressing question among scientists of just how close mice are to people when it comes to researching cancer. The findings, now published…

Photo

RSNA 2015

Breast MRI after mammography may identify additional aggressive cancers

Additional breast cancers found with MRI are sometimes larger and potentially more aggressive than those found on mammography, according to a study published online in the journal Radiology.

Photo

How to tame most aggressive breast cancers

Australian researchers have found that so-called 'triple-negative breast cancers' are two distinct diseases that likely originate from different cell types. This helps explain why survival prospects…

Related products

Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Agena Bioscience - MassARRAY Colon Panel

Amplification/Detection

Agena Bioscience - MassARRAY Colon Panel

Agena Bioscience GmbH
Beckman Coulter – Remisol Advance

LIS, Middleware, POCT

Beckman Coulter – Remisol Advance

Beckman Coulter, Inc.
Eppendorf – BioSpectrometer fluroescence

Research Use Only (RUO)

Eppendorf – BioSpectrometer fluroescence

Eppendorf AG
Eppendorf – μCuvette G1.0

Research Use Only (RUO)

Eppendorf – μCuvette G1.0

Eppendorf AG